Blood eosinophil counts as markers of response to inhaled corticosteroids in COPD? - Authors' reply

The Lancet Respiratory Medicine

Volumn 3, Issue 8, 2015, Pages e27-

  Pascoe, Steven ^a   Locantore, Nicholas ^a   Dransfield, Mark T ^b,c   Barnes, Neil C ^d,e   Pavord, Ian ^f  

^a GLAXOSMITHKLINE   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c BIRMINGHAM VA MEDICAL CENTER   (United States)

^d GLAXOSMITHKLINE   (United Kingdom)

^e QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^f UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE; BENRALIZUMAB; BIOLOGICAL MARKER; CORTICOSTEROID; OLODATEROL PLUS TIOTROPIUM BROMIDE; SALBUTAMOL; ANDROSTANE DERIVATIVE; BENZYL ALCOHOL DERIVATIVE; BRONCHODILATING AGENT; CHLOROBENZENE;

ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL (TOPIC); DISEASE EXACERBATION; DISEASE MARKER; EOSINOPHIL COUNT; FORCED EXPIRATORY VOLUME; HUMAN; INFLAMMATION; LETTER; PRIORITY JOURNAL; RISK ASSESSMENT; SPUTUM CULTURE; TH2 CELL; TREATMENT RESPONSE; BLOOD; DRUG EFFECTS; EOSINOPHIL; FEMALE; MALE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

ANDROSTADIENES; BENZYL ALCOHOLS; BRONCHODILATOR AGENTS; CHLOROBENZENES; EOSINOPHILS; FEMALE; HUMANS; MALE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84939427104     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(15)00259-3     Document Type: Letter

References (10)

1. Pascoe S, Locantore N, Dransfield MT, Barnes NC, Pavord ID Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med 2015, 3:435-442.
2. Buhl R, Maltais F, Abrahams R, et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4). Eur Respir J 2015, 45:969-979.
3. DiSantostefano RL, Hinds D, Van Le H, Barnes N Characteristics associated with higher blood eosinophil percent in subjects with COPD in the National Health and Nutrition Examination survey (NHANES 2007-10). Am J Respir Crit Care Med 2015, 191:A2868.
4. Siddiqui SH, Guasconi A, Vestbo J, et al. Blood eosinophils: a biomarker of response to extrafine beclomethasone/formoterol in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2015, published online June 6. 10.1164/rccm.201502-0235LE.
5. Hinds D, De Stefano R, Pascoe S COPD patient clusters that benefit most from fluticasone furoate added to vilanterol (FF/VI) versus vilanterol (VI). Am J Respir Crit Care Med 2015, 191:A3980.
6. Christenson SA, Steiling K, van den Berge M Asthma-COPD Overlap. Clinical relevance of genomic signatures of Type 2 inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2015, 191:758-766.
7. Brightling CE, Bleecker ER, Panettieri RA, et al. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study. Lancet Respir Med 2014, 2:891-901.
8. Bafadhel M, Mckenna S, Terry S, et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Am J Respir Crit Care Med 2012, 186:48-55.
9. A study comparing the efficacy, safety and tolerability of fixed dose combination (FDC) of FF/UMEC/VI with the FDC of FF/VI and UMEC/VI; administered once-daily via a dry powder inhaler (DPI) in subjects with chronic obstructive pulmonary disease (COPD). (accessed July 15, 2015). https://clinicaltrials.gov/ct2/show/NCT02164513?term=Fluticasone+furoate+COPD+exacerbations&rank=29.
10. Magnussen H, Disse B, Rodriguez-Roisin R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med 2014, 371:1285-1294.